NCT03206346View on ClinicalTrials.gov

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

August 31, 2013

Conditions
Influenza, HumanAcute Respiratory InfectionViral InfectionCommon Cold
Interventions
DRUG

Ingavirin

Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.

DRUG

Placebo oral capsule

Placebo, capsules daily for 5 days.

Trial Locations (5)

150000

"GBOU VPO Yaroslavl State Medical University of Ministry of Health of Russian Federation", Yaroslavl

197376

Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Saint Petersburg

410012

Saratov State Medical University named after V. I. Razumovsky, Saratov

420012

"GBOU VPO Kazan State Medical University of Ministry of Health of Russian Federation", Kazan'

614066

City Pediatric Outpatient Clinic number 5, Perm

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY

NCT03206346 - Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o. | Biotech Hunter | Biotech Hunter